MK-431 (Merck)

Curr Opin Investig Drugs. 2005 Apr;6(4):419-26.

Abstract

Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.

Publication types

  • Review

MeSH terms

  • Adenosine Deaminase / pharmacology
  • Adenosine Deaminase / therapeutic use*
  • Adenosine Deaminase Inhibitors*
  • Animals
  • Clinical Trials as Topic
  • Contraindications
  • Dipeptidyl Peptidase 4 / pharmacology
  • Dipeptidyl Peptidase 4 / therapeutic use*
  • Drug Industry / methods
  • Drug Industry / trends
  • Glycoproteins / antagonists & inhibitors*
  • Glycoproteins / pharmacology
  • Glycoproteins / therapeutic use*
  • Humans
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Pyrazines / adverse effects
  • Pyrazines / chemistry
  • Pyrazines / therapeutic use*
  • Sitagliptin Phosphate
  • Triazoles / adverse effects
  • Triazoles / chemistry
  • Triazoles / therapeutic use*

Substances

  • Adenosine Deaminase Inhibitors
  • Glycoproteins
  • Hypoglycemic Agents
  • Protease Inhibitors
  • Pyrazines
  • Triazoles
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4
  • Adenosine Deaminase
  • Sitagliptin Phosphate